Becton Dickinson and Company (NYSE:BDX) went up by 0.18% from its latest closing price compared to the recent 1-year high of $284.97. The company’s stock price has collected -3.39% of loss in the last five trading sessions. MarketWatch.com reported 7 hours ago that Becton Dickinson & Co. stock outperforms market on strong trading day
Is It Worth Investing in Becton Dickinson and Company (NYSE :BDX) Right Now?
Becton Dickinson and Company (NYSE:BDX) scored a price-to-earnings ratio above its average ratio, recording 47.50 x from its present earnings ratio. Plus, the 36-month beta value for BDX is at 0.75. Opinions of the stock are interesting as 10 analysts out of 18 who provided ratings for Becton Dickinson and Company declared the stock was a “buy,” while 2 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $281.57, which is $34.42 above the current price. BDX currently public float of 288.64M and currently shorts hold a 0.69% ratio of that float. Today, the average trading volume of BDX was 1.40M shares.
BDX’s Market Performance
BDX stocks went down by -3.39% for the week, with a monthly drop of -4.34% and a quarterly performance of 8.17%, while its annual performance rate touched 0.41%. The volatility ratio for the week stands at 2.33% while the volatility levels for the past 30 days are set at 2.18% for Becton Dickinson and Company. The simple moving average for the period of the last 20 days is -2.91% for BDX stocks with a simple moving average of 0.12% for the last 200 days.
Analysts’ Opinion of BDX
Many brokerage firms have already submitted their reports for BDX stocks, with Morgan Stanley repeating the rating for BDX by listing it as a “Overweight.” The predicted price for BDX in the upcoming period, according to Morgan Stanley is $297 based on the research report published on December 15th of the previous year 2020.
Wells Fargo, on the other hand, stated in their research note that they expect to see BDX reach a price target of $265. The rating they have provided for BDX stocks is “Equal Weight” according to the report published on December 15th, 2020.
Barclays gave a rating of “Overweight” to BDX, setting the target price at $300 in the report published on July 09th of the previous year.
BDX Trading at -2.49% from the 50-Day Moving Average
After a stumble in the market that brought BDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.27% of loss for the given period.
Volatility was left at 2.18%, however, over the last 30 days, the volatility rate increased by 2.33%, as shares sank -1.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.84% upper at present.
During the last 5 trading sessions, BDX fell by -3.39%, which changed the moving average for the period of 200-days by -5.69% in comparison to the 20-day moving average, which settled at $254.36. In addition, Becton Dickinson and Company saw -1.23% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BDX starting from Goette Roland, who sale 930 shares at the price of $230.10 back on Nov 23. After this action, Goette Roland now owns 7,994 shares of Becton Dickinson and Company, valued at $213,993 using the latest closing price.
Kaltenbach Patrick, the EVP & Pres Life Sciences of Becton Dickinson and Company, sale 1,272 shares at $260.00 during a trade that took place back on Jul 09, which means that Kaltenbach Patrick is holding 10,340 shares at $330,720 based on the most recent closing price.
Stock Fundamentals for BDX
Equity return is now at value 6.50, with 2.80 for asset returns.